← Back to Search

Diagnostic Test

Multidisciplinary Screening for Heart Failure (MAPLE-CHF Trial)

N/A

Recruiting

Led By Serge LePage, MD

Research Sponsored by Cardiology Research UBC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Regular loop diuretic use for >30 days within 12 months prior to consent

Previous ischemic or embolic stroke

Timeline

Screening 3 weeks

Treatment Varies

Follow Up enrollment to six months

Awards & highlights

MAPLE-CHF Trial Summary

This trial aims to improve screening for heart failure & identify those at risk earlier than usual care.

Who is the study for?

This trial is for adults over 40 with risk factors like coronary artery disease, diabetes, atrial fibrillation, stroke history, regular diuretic use, COPD, peripheral artery disease or chronic kidney disease. It's not for those who can't consent, already have heart failure diagnosis or are on renal replacement therapy.Check my eligibility

What is being tested?

The study tests if a special algorithm to find heart failure signs in electronic health records plus additional screening (NT-proBNP blood test and AI echocardiogram) can detect heart failure earlier compared to usual care methods.See study design

What are the potential side effects?

There may be minimal side effects related to the cardiovascular physical examination and drawing of blood. The NT-proBNP test is generally safe but might cause slight discomfort. Echocardiograms and electrocardiograms are non-invasive and typically don't have side effects.

MAPLE-CHF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been using water pills regularly for over a month in the past year.

Select...

I have had a stroke caused by a clot.

Select...

I have had a heart attack or surgery/intervention for blocked heart arteries.

Select...

I have ongoing or permanent irregular heartbeats.

Select...

I have diabetes.

Select...

I have chronic kidney disease with specific test results.

Select...

I am over 40 years old.

Select...

I have had surgery or a procedure for blocked arteries in my legs.

MAPLE-CHF Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ enrollment to six months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~enrollment to six months

This trial's timeline: 3 weeks for screening, Varies for treatment, and enrollment to six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of HF hospitalizations

Number of outpatient HF visits

Number of participants diagnosed with heart failure (HF) according to the European Society of Cardiology 2021 HF guidelines

+1 more

Secondary outcome measures

HF events in HFrEF

incidence of prescription for guideline recommended HF therapies in patients diagnosed with HFrEF

MAPLE-CHF Trial Design

2Treatment groups

Active Control

Group I: Investigational arm guided by NT-proBNP resultActive Control4 Interventions

NT-proBNP drawn and if level elevated (>125 pg/ml) a study visit with artificial intelligence (AI) echocardiogram, electrocardiogram (ECG), and heart failure (HF) focused examination conducted

Group II: Routine care armActive Control1 Intervention

Participants will be remotely monitored for number of heart failure events

0 / 8Eligibility criteria met

Find a Location

Who is running the clinical trial?

Cardiology Research UBCLead Sponsor

15 Previous Clinical Trials

5,787 Total Patients Enrolled

Centre for Cardiovascular InnovationUNKNOWN

NHS Greater Glasgow & ClydeUNKNOWN

Media Library

AI echocardiogram (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT05859048 — N/A

Heart Failure Research Study Groups: Investigational arm guided by NT-proBNP result, Routine care arm

Heart Failure Clinical Trial 2023: AI echocardiogram Highlights & Side Effects. Trial Name: NCT05859048 — N/A

AI echocardiogram (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05859048 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities to be part of this research study?

"The information posted on clinicaltrials.gov reveals that, as of May 11th 2023, this trial is no longer actively looking for participants. Nonetheless, there are 728 other medical studies enrolling patients at the moment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure

Nathaniel Hawkins 2024. "Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05859048.